WuXi AppTec Co., Ltd. (2359.HK)
| Previous Close | 35.450 |
| Open | 35.000 |
| Bid | 38.350 x 0 |
| Ask | 38.400 x 0 |
| Day's Range | 34.350 - 39.050 |
| 52 Week Range | 32.600 - 103.600 |
| Volume | |
| Avg. Volume | 9,688,253 |
| Market Cap | 144.974B |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | 10.97 |
| EPS (TTM) | 3.500 |
| Earnings Date | Jul 29, 2024 - Aug 02, 2024 |
| Forward Dividend & Yield | 0.99 (2.79%) |
| Ex-Dividend Date | Jun 05, 2023 |
| 1y Target Est | 68.09 |
PR NewswireWuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations
WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the first quarter ending March 31, 2024 ("Reporting Period"):
ReutersExclusive-China's WuXi AppTec shared US client's data with Beijing, US intelligence officials told senators
(Reuters) -U.S. intelligence officials in late February told senators working on a biotech security bill that Chinese pharmaceutical firm WuXi AppTec had transferred U.S. intellectual property to Beijing without consent, according to two sources. The U.S. government is concerned that certain Chinese biotech companies are contributing technology or research and development for use by China's military, and the proposed legislation would restrict U.S. government funds going to those Chinese companies. The classified briefing to about a dozen senators was led by the FBI, the State Department and the Office of the Director of National Intelligence.
PR NewswireWuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time
WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the year ending December 31, 2023 ("Reporting Period"):
